Canada-based Bausch Health Companies (TSX: BHC) and its gastroenterology business, Salix Pharmaceuticals, have agreed to resolve a set of outstanding intellectual property disputes with India's Sun Pharmaceutical (BSE: 524715).
Starting April 2019, the litigation relates to the antibiotic product Xifaxan (rifaximin).
Developed by US drugmaker Salix, Xifaxan treats diarrhea by altering the gut flora. The product was used off-label for this purpose for many years, before at last gaining approval in 2015, based on positive data.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze